Novel amodiaquine analogues to treat cervical cancer and microbial infection in the future

Future Med Chem. 2023 Dec;15(23):2165-2179. doi: 10.4155/fmc-2023-0245. Epub 2023 Nov 20.

Abstract

Aim: To synthesize and explore the therapeutic potential of amodiaquine analogues. Methodology: New promising analogues were synthesized by nucleophilic substitution at the 4-amino position and were characterized using 1H NMR, 13C NMR and FT-IR spectroscopic techniques. Results: Antibacterial and cytotoxic screening revealed the high potency of these compounds; analogue AS1 had an 34.3 ± 0.18 mm zone of inhibition against Pseudomonas aeruginosa. Excellent activity against fungal strains, that is, Candida albicans (39.6 ± 0.23 mm) was shown by analogue AS2. Analogue AS1 had an IC50 = 4.2 μg/ml against the HeLa cell line (cervical cancer) and binding energy against 5GWK (-8.32688 kcal/mol), 1PFK (-6.4780 kcal/mol) and 1TUP (-6.5279 kcal/mol) in the docking study. Conclusion: The obtained results reveal that these analogues exhibit potent antimicrobial and cytotoxic potential.

Keywords: amodiaquine analogues; drug repositioning; inhibitory concentration; sulfonamide.

MeSH terms

  • Amodiaquine / pharmacology
  • Anti-Bacterial Agents / chemistry
  • Anti-Bacterial Agents / pharmacology
  • Antineoplastic Agents* / chemistry
  • Antineoplastic Agents* / pharmacology
  • Candida albicans
  • Female
  • HeLa Cells
  • Humans
  • Microbial Sensitivity Tests
  • Molecular Docking Simulation
  • Molecular Structure
  • Spectroscopy, Fourier Transform Infrared
  • Structure-Activity Relationship
  • Uterine Cervical Neoplasms* / drug therapy

Substances

  • Amodiaquine
  • Antineoplastic Agents
  • Anti-Bacterial Agents